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Context. Opioids are essential medicines. The World Health Organization and
Health Action International monitor the price of essential medicines. However,
their surveys do not include opioids, and there is no information on their
affordability.
Objectives. To provide information on access to pain treatment, as measured by
the availability and dispensed price of five opioids in 13 formulations, and the
affordability of oral immediate-release (IR) morphine.
Methods. The International Association for Hospice and Palliative Care
members were distributed by their countries’ Gross National Income (GNI) level
using the World Bank categories, i.e., high income country (HIC), upper middle
income country (UMIC), lower middle income country (LMIC), low income
country (LIC), and randomized. A total of 10 participants were selected from each
(n¼ 40) domain. Participants were asked to identify a pharmacy located closest to
a public facility that provides diagnosis/treatment for life-threatening conditions
and report the lowest dispensed price of the smallest selling unit and strength of
each formulation. Availability and median (Me) price were calculated for each.
Affordability and percentage of international buyer price (IBP) were calculated
for morphine oral solid IR.
Results. A total of 30 participants from 26 countries (response rate¼ 75%)
responded. Significant correlation was found between availability and GNI
(range: 65e68% [HIC and LIC]; R¼ 0.781; P< 0.0001). Injectable and
morphine oral solid sustained release (SR) were the most available (59% and
55%). Methadone (oral) was the least expensive (Me¼ 0.5) followed by fentanyl
(transdermal; Me¼ 2.2). The Me price for morphine oral solid IR and ratios
between dispensed and IBP were lower in HIC than in LMIC (price¼ 0.03 vs.Address correspondence to:LilianaDeLima,MHA, Inter-
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650 Vol. 48 No. 4 October 2014De Lima et al.0.16; ratio¼ 2.23 vs. 0.03). Affordability for morphine oral solid IR was five days
(Me¼ 0.1; range¼ 29e0.25).
Conclusion. Patients in LMIC and LIC have limited access to opioids, and there
are subsidies in place for more expensive medications and formulations in all GNI
levels, but not for morphine oral solid IR. Additional research is necessary to
identify the reasons behind these findings. J Pain Symptom Manage
2014;48:649e659.  2014 American Academy of Hospice and Palliative Medicine.
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Introduction
The World Health Organization (WHO)
recognizes palliative care and pain relief as
critical public health issues.1e3 Strong opioids
are a cornerstone of pain treatment, of which
morphine is considered essential by the WHO.4
In 2007, the International Association for Hos-
pice and Palliative Care (IAHPC) developed a
list of Essential Medicines (EMLs) in Palliative
Care,5 which includes opioids for the treatment
of pain and other symptoms. Still, inmany coun-
tries, limited or no access is a significant prob-
lem. Developing countries with about 80% of
the world population account for 6% of the
global morphine consumption3 resulting inmil-
lions of patients suffering needlessly.
Access to opioids is limited owing to several
reasons, including restrictive drug control laws
and regulations, lack of education, and high
prices.6,7 In developing countries, they have
been reported to be more expensive than in
developed nations,8e11 and prices in small cities
and rural areas are higher than in large cities.12
Opioid pricing is impacted by additional fac-
tors, such as markups resulting from safety
and security measures required by the national
laws on the manufacturing, importation, distri-
bution, storage, and dispensation of controlled
medicines. Pricing is also affected by the type of
formulation, namely complex delivery mecha-
nisms, such as transdermal patches (TPs); trans-
mucosal or SR formulations are costlier tomake
than immediate release (IR) oral formulations
(solid or liquid).
The WHO and Health Action International
(HAI) developed a method to monitor and
report the price of essential medicines as
a measure of access,13 which has prompted
some governments to lower the cost ofmedicines. However, with one exception,
the WHO/HAI surveys do not include opioids,
and there is limited information on their price
and affordability. In 2008, the IAHPC decided
to develop theOpioid PriceWatch (OPW) Proj-
ect as a component of the agreement of work as
a nongovernmental organization in formal
relations with the WHO. This article describes
the pilot study implemented to test the OPW.
Objectives
The objectives of the article are to:
1. Provide information on opioid availability
globally;
2. Show opioid price patterns among regions
and countries, as reflected in differences
in treatment costs, affordability, and dif-
ferences in prices as a ratio of the interna-
tional reference price; and
3. Allow further analysis of the difficulties
in availability and affordability of opioid
analgesics and suggest possible strategies
addressing the identified problems.Methods
The study design was a cross-sectional study.16
The project proposal is available on the IAHPC
web site in http://hospicecare.com/resources/
opioid-price-watch/. An ethics review board
from the Fundacion FederacionMedica de Bue-
nos Aires in Argentina approved the study.
The opioids were selected using the
following criteria:
1. Included in the 17th edition of the WHO
Model EMLs4
2. Included in the IAHPC EML but not
included in the WHO EML5
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were selected.
1. Fentanyl TPs
2. Hydromorphone (injectable, oral liquid,
oral solid IR, and oral solid SR)
3. Methadone (oral liquid and oral solid)
4. Morphine (injectable, oral liquid, and
oral solid [IR and SR])
5. Oxycodone (oral solid IR and SR)
All member states of the United Nations
report consumption of these medications to
the International Narcotics Control Board.17
The study sample was selected using the
IAHPC members’ list following a stratified
random sampling:
1. The IAHPC members were listed by coun-
try in alphabetical order.
2. Countries were stratified by their Gross
National Income (GNI) using the World
Bank categories: low income countries
(LICs), low middle income countries
(LMICs), upper middle income countries
(UMICs), and high income countries
(HICs).18
3. The IAHPC members were listed by their
corresponding country’s GNI and each
list was randomized.19
4. The first 10 participants in each category
were selected, resulting in 40 potential
participants.
Selected individuals were contacted by
e-mail and invited to participate. Whenever
one declined the invitation or if he/she did
not reply, the next individual in the list was
invited.
Participants were informed of the objectives
of the study, total estimated time to complete
the survey, that their names would be acknowl-
edged, and that the data presented would be
linked to their countries. A signed informed
consent was submitted by all before completing
the survey. Participants were asked to select the
pharmacy located closest to a public health fa-
cility that provides diagnostic and treatment
services for patients with life-threatening condi-
tions. They were asked to speak to the chief
pharmacist. A letter describing the project
and identifying them as participants of the
study was shown to the pharmacist. Participants
were instructed to inquire if at least one of the
opioids included in the study was available anddispensed for ambulatory patients. If opioids
were not available or the pharmacist was unwill-
ing to cooperate, they were asked to go to the
next nearest pharmacy and to continue this
process until they located one pharmacy that
had at least one opioid available and where
the chief pharmacist was willing to collaborate.
Participants were asked to record in their local
currency the lowest retail dispensed price of the
smallest selling dose and unit for the opioid for-
mulations available on the day they completed
the survey. The address of the surveyed phar-
macy was also recorded to avoid potential dupli-
cation. The Appendix (available at jpsmjournal.
com) includes a sample of the survey form.
The completed survey was submitted via
the IAHPC server http://hospicecare.com/
opioids/reports/add. Data were collected
from September 2012 to April 2013. Prices
were converted to U.S. Dollars (USD) using
Google Finance Converter.20 Survey results
were exported to Microsoft Excel and IBM
SPSS Statistics 21.
Definitions
The following definitions were applied in
the study:13
Accessibility: The extent that patients
can obtain the opioid medications they need
for pain reliefdpatient access is not possible
unless opioids are available and affordable.
Affordability: Total number of days required
by a patient earning the minimum wage to pur-
chase a 30-day treatment of medications at the
dispensed price.21
Availability: Existence of the opioid medi-
cation in stock at the pharmacy to be
dispensed to patients arriving at the phar-
macy with a legitimate medical prescription.
It was calculated by the percentage of opioids
available at the moment the survey was
completed, with 13 being the maximum num-
ber of formulations. The amount of pharma-
cies visited before finding one that had any of
the opioids included in the study was
recorded.
Dispensed Price: Pharmacy selling price plus
any fees and any sales taxes. Dispensed price
for a 30-day treatment for each medication
was calculated by dividing the price of the
package/bottle by the total milligrams in
each, and then multiplying the resulting price
per milligram by the corresponding monthly
652 Vol. 48 No. 4 October 2014De Lima et al.treatment of the Defined Daily Dose (DDD;13
Table 1). The DDD is the average maintenance
dose per day for a drug used for its main indi-
cation in adults established by the WHO
Collaborating Center for Drug Statistics Meth-
odology.22,23 The DDD is a quantitative mea-
sure for statistical purposes only and not to
be used as a treatment guideline.
Median (Me) Price: The middle value in a
distribution, above and below which lie an
equal number of the highest and lowest prices
recorded for each medication.
Median Price Ratio (MPR): Difference
between the reported dispensed price and
the international buyer reference price given
by the International Drug Price Indicator
Guide.24Data Analysis
This article presents results and analysis of
the following data:
1. For five opioids in 13 formulations: avail-
ability, dispensed price of lowest dosage
available, and Me price of each.
2. For morphine oral solid IR: In addition to
the Dispensed price, the MPR and Afford-
ability were also calculated for this medica-
tion and formulation. The reason is that
morphine oral solid IR has been used as
a reference for monitoring consumption
of opioids, and it is included as the gold
standard essential strong analgesic in the
WHO Model EMLs.4
A descriptive analysis of the data and a
comparative analysis by GNI region wereTable 1
Amount Needed for a 30-Day Treatment for
Each Medication
MedicationdFormulation DDD (mg)
30-Day
Treatment
(DDD 30)21
Fentanyldtransdermal 0.0012 36
Hydromorphonedoral 20 600
Hydromorphonedinjectable 4 120
Morphinedoral (IR and SR) 100 3000
Morphinedinjectable 30 900
Oxycodonedoral 75 2250
Methadonedorala 20 600
DDD¼Defined Daily Dose; IR¼ immediate release; SR¼ sustained
release.
aGiven that there is no identified DDD for pain treatment with
methadone, a morphine equivalent dose was defined as 1:5 based
on the published literature:22 (100 mg/5¼ 20 mg).conducted. Given the sample size, Spearman’s
rank correlation coefficients (Rs) and Kruskal-
Wallis tests were used when applicable.Results
Data were submitted by 30 participants from
26 countries (75% response rate). Participants
are listed in the Acknowledgment section.
Reports were submitted from two locations in
two countries, namely China (Beijing and
Chengdu) and the U.K. (Edinburgh and
Leeds); whereas reports from three locations
were submitted from Tanzania (two in Arusha
and one in Dar es Salaam). Reports from Aru-
sha (Arusha 1 and 2) were the same for avail-
ability and prices. In Chile and Poland, the
survey was submitted by the invited participant
and an additional collaborator, not included in
the response rate but listed in the Acknowledg-
ment section.
Availability
The average number of pharmacies visited
before finding the one that had at least
one of the opioids included in the study varied
by GNI: HIC: 1 (range¼ 0e1, Me¼ 0.6),
UMIC: 1 (range¼ 0e2, Me¼ 1), LMIC: 9
(range¼ 1e40, Me¼ 2.5), and LIC: 4.5
(range¼ 3e15, Me¼ 6.1). In Moldova, Nepal,
and Sudan, opioids are available only in hospi-
tal pharmacies allowed to dispense for nonhos-
pitalized patients.
Availability of opioid formulations ranged
from11 (85%) inNorway to 0 in Kenya,Nigeria,
Tanzania (Dar es Salaam), and Uganda. In five
locations (Bangladesh, Brazil, Ethiopia,
Tanzania [Arusha 1 and 2], and Uruguay),
only one opioid was available, followed by Mol-
dova with two. Norway had the highest number
available,11 followed by Germany, New Zealand,
and Spain.9
The mean percentage of medications avail-
able is strongly related to GNI level, ranging
from 65% to 8% (HIC and LIC, respectively;
Table 2). A significant positive correlation be-
tween the country’s GNI and the availability
of opioids was found (Rs¼ 0.781;
P< 0.0001). In all HIC, availability was higher
than 50%, with the exception of Poland
(46%). Brazil and Uruguay had the lowest
availability in the UMIC group (8%), whereas
Vol. 48 No. 4 October 2014 653Access to Opioids Around the Globethe highest availability was in China (Cheng-
du) and Romania (almost 50%). The extremes
of the LMIC groups were Guatemala and
Nigeria (62% and 0%, respectively). Nepal
stands out in the LIC group with 31% of the
medications available.
Injectablemorphine (ampoule) was themost
available (58%, n¼ 17), followed by morphine
oral solid SR (53%, n¼ 16), then by morphine
oral solid IR, fentanyl TP, and oxycodone SR
(47%, n¼ 14). Morphine ampoule was avail-
able in three of the LIC (Bangladesh, Ethiopia,
and Nepal), whereas morphine liquid was avail-
able in Nepal and Tanzania (Arusha 1 and 2).
No opioids were available in Kenya, Nigeria,
Tanzania (Dar es Salaam), or Uganda, but
none reported that the opioids were never avail-
able. Hydromorphone was the least available of
all: liquid (none), ampoule (China [Beijing]),
IR solid (Norway and China [Beijing]), and
SR solid (Germany, Norway, and Spain).
Dispensed Prices
Opioids are dispensed free in Chile, Moldo-
va, Nepal, New Zealand, Russia, Sudan, andTable 2
Availability of Opioids by
Income Group (GNI) Mean Percenta C
HIC 64.8 Norway
German
New Zea
Spain (P
U.K. (Le
U.K. (Ed
Poland (
UMIC 29.1 China (C
Romania
Chile (S
Iran (Te
Argentin
China (B
Russia (K
Brazil (R
Uruguay
LMIC 28.2 Guatema
Philippin
India (N
Sudan (K
Moldova
LIC 7.7 Nepal (B
Ethiopia
Tanzania
Tanzania
Tanzania
Kenya (N
Uganda
GNI¼Gross National Income; HIC¼ high income country; UMIC¼ upper
LIC¼ low income country.
aSpearman’s rank correlation coefficient (Rs)¼ 0.781; P< 0.0001, Kruskal-WaTanzania (Arusha 1 and 2). In Edinburgh, opi-
oids are free, but not in Leeds (U.K.). In Ger-
many, medications are dispensed at no cost to
the patients through a health insurance fund,
but patients are required to pay a fixed
dispensing fee.
The Me price for morphine oral solid IR
10 mg ranged between USD 0.03 and 0.16 for
HIC and LMIC, respectively, whereas the MPR
ranged between USD 0.06 and 0.33 in HIC
and LMIC, respectively (Table 3). Table 4
describes the Me price comparison of a 30-day
treatment by GNI. The Me price of 30-day treat-
ment of morphine oral solid IR 10 mg was less
in HIC (USD 4.6) than in lower GNI groups
(UMC¼ 30.5 and LM¼ 46.8). Apart from
morphine liquid, which is free in seven of
13 countries (Me¼ 0), methadone oral solid
was the lowest-priced medicine (Me¼ 0.5), fol-
lowed by fentanyl TP (Me¼ 2.2). Synthetic opi-
oids and in some cases opioids with more
complex delivery mechanisms (TP and oral
SR) were dispensed at lower prices than
morphine oral solid IR. Fentanyl TP is free in
Chile, Iran, New Zealand, Romania, and RussiaIncome Groups
ountry (City) % Of Opioids Available
(Bergen) 84.62
y (Aachen) 69.23
land (Wellington) 69.23
amplona) 69.23
eds) 61.54
inburgh) 53.84
Poznan) 46.15
hengdu) 46.15
(Brasov) 46.15
antiago) 38.46
heran) 38.46
a (San Nicolas) 30.77
eijing) 23.08
emerovo) 23.08
io de Janeiro) 7.69
(Montevideo) 7.69
la (Guatemala City) 61.54
es (Iloilo City) 38.46
ew Delhi) 30.77
hartoum) 23.08
(Chisinau) 15.38 Nigeria (Ibadan)
haratpur) 30.77 Bangladesh (Dhaka)
(Hawassa) 7.69
(Arusha 1) 7.69
(Arusha 2) 7.69
(Dar es Salaam) 0
airobi) 0
(Kampala) 0
middle income country; LMIC¼ lower middle income country;
llis tests P< 0.0001.
Table 3
Morphine Oral Solid, IR 10 mg TabletdMedian
Price Per Unit and Median Price Ratio (MPR) by
Income Groups
GNI Group
Median Price (10 mg),
USD MPR
HIC 0.03 0.06
UMIC 0.10 0.22
LMIC 0.16 0.33
LIC d d
GNI¼Gross National Income; HIC¼ high income country;
UMIC¼ upper middle income country; LMIC¼ lower middle
income country; LIC¼ low income country.
MPR¼ difference between the reported dispensed price and the
international buyer reference price. The 2011 international buyer
reference price for morphine oral solid IR 10 mg tablet was USD
0.47.24
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654 Vol. 48 No. 4 October 2014De Lima et al.and the least expensive in Germany, Guatemala,
India, Norway, Philippines, Poland, Spain, and
theU.K. (Leeds). In general, it was found that if
available, patients in LMIC are likely to pay
more for the medication than patients in the
other two groups. Hydromorphone oral solid
IR was the most expensive formulation
(Me¼ 228.5) followed by oxycodone (IR:
Me¼ 144.1; SR: Me¼ 112.6).
Affordability
The mean number of days’ wages required
by the lowest-paid worker to purchase a 30-
day treatment of morphine oral solid IR
among the 14 countries that reported avail-
ability was five days (Me¼ 0.1; SD¼ 9.1), but
varies greatly by country, ranging from:
29.48 (Philippines) and 20.75 (India) to
0.25 days (Spain). In five countries (Nepal,
Sudan, Romania, New Zealand, and Poland),
it is dispensed free to patients. The results
indicate that morphine oral solid IR is less
affordable in countries in lower income
groups: LMIC (Me¼ 14.4; mean¼ 14.6
[SD¼ 13.1]), UMIC (Me¼ 2.2; mean¼ 2.7
[SD¼ 9.3]), and HIC (Me¼ 0.2 [SD¼ 0.36];
Table 5). In general, a negative correlation
between the days’ wages and the country in-
come category (Rs¼ 0.544; not significant)
was identified: the lower the income, the
more working days required to pay for the
treatment.M
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This is the first pilot study that presents
information on the differences among
Table 5
Affordability for a 30 Day Treatment of
Morphine Oral Solid IR by Income Group
GNI
Group
Number of
Days’ Wages Country
Number of
Days’ Wages
All Me¼ 0.1
IQR¼ 6.9
x ¼ 5$0
CI¼ 4.76
All countries
HIC Me¼ 0.0
IQR¼ 0.5
x ¼ 0.2
CI¼ 0.32
U.K. (Leeds) 0.8
Spain 0.3
New Zealand 0.0
Poland 0.0
Norway a
UMIC Me¼ 2.2
IQR¼ 6.0
x ¼ 2.7
CI¼ 3.19
Argentina 6.5
China (Chengdu) 4.5
Romania 0.0
LMIC Me¼ 14.4
IQR¼ 25.3
x ¼ 14.6
CI¼ 12.84
Philippines 29.5
India 20.8
Guatemala 8.1
Sudan 0.0
LIC Me¼ 0.0
IQR¼ 0.0
x ¼ 0.0
CI¼ 0.0
Nepal 0.0
GNI¼Gross National Income; Me¼median; IQR¼ interquartile
range; x ¼mean; CI¼ confidence interval; HIC¼ high income
country; UMIC¼ upper middle income country; LMIC¼ lower
middle income country; LIC¼ low income country; IR¼ immedi-
ate release.
aMorphine oral solid IR was available in Norway; however, it was
not possible to determine the affordability given that there is no
minimum wage in the country.
Vol. 48 No. 4 October 2014 655Access to Opioids Around the Globeavailability, prices, and affordability of opioids
across the World Bank GNI groups in pharma-
cies close to a public health facility that pro-
vides diagnostic and treatment services for
patients with life-threatening conditions such
as HIV and cancer.Availability
The information reflects opioid availability
in a specific pharmacy on any given day, so
no inferences regarding availability in the
whole country are possible. Although results
indicate that several opioids and formulations
were not available at the time of the survey, it
does not imply that these opioids are never
available in such locations. None of the coun-
tries included in the study reported not having
any opioids available at any time, which is an
indication of progress.7 The possibility of
finding an opioid at the pharmacy is directly
correlated to the country’s GNI, which is
consistent with opioid consumption reports
published by the International Narcotics Con-
trol Board. The number of medicationsavailable in Guatemala was high compared
with countries within the middle and low
GNI, which may reflect recent efforts to
improve availability to pain treatment in that
country. Almost all the African countries regis-
tered very limited availability, with either none
or one opioid available, with the exception of
Sudan, which reported having three medica-
tions/formulations available. The partici-
pating African countries were LIC (Ethiopia,
Kenya, Tanzania, and Uganda) or LMIC
(Nigeria and Sudan). Recent efforts have
been made to improve opioid availability in
several African countries, so future OPW re-
ports should reflect increased availability in
these countries as well. As suggested by the
WHO,13 the availability of medications can be
improved through adequate management
and realistic assessment of local supply options
and needs.
While this report was being prepared, the
WHO published a new edition of the EML,
which includes all the morphine formulations
and lists oxycodone and hydromorphone as
substitutes for morphine.25
The WHO Model List also includes a new
section of medications for pain and other
symptoms common in palliative care, which
will hopefully result in increased awareness
about the importance and relevance of hav-
ing these medications available to relieve
suffering of patients with life-threatening
conditions.
Dispensed Prices
In regard to its international reference price
(USD 0.47), the Me price of morphine oral
solid IR (10 mg) is 5.8 times higher in LMIC
than in HIC. In the former, the cost of addi-
tional burdens and requirements resulting
from stringent norms and regulations may be
transferred on to the patients, whereas in
HIC, the costs tend to be covered through
other funds and pooling of resources.26
Hydromorphone oral IR and oxycodone oral
IR and SR were the highest dispensed price
medications. However, in Iran and Norway,
the dispensed price of oxycodone oral IR was
lower thanmorphine injectable; and in Poland,
the dispensed price of oxycodone oral SR was
lower than methadone oral liquid. Results
also show an unexpected favorable price differ-
ence for fentanyl TP: it is dispensed free in five
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est opioid in seven, indicating that there could
be heavy subsidies in place at all GNI levels. For
example, morphine oral solid IR tablet was
more expensive than fentanyl TP in China
(Chengdu), Germany, Guatemala, India, Iran,
Norway, Poland, Spain, the Philippines, and
the U.K. It would be useful to find out the rea-
sons why morphine is not included in subsidy
programs, even in LMIC. Artificially lowering
the dispensing price of the most expensive
medications and formulations results in an eco-
nomic disadvantage for morphine oral solid IR
and probably also in less demand for this medi-
cation. Morphine oral IR is cheaper than other
opioids,10,27,28 so there may be insufficient
margin to generate profit incentive for phar-
maceutical companies to commercialize it.
Although availability of several opioids and for-
mulations is desirable, it is also critical to
ensure access to morphine oral solid IR solid,
which has been proven to be efficacious and
safe for treatment of severe pain.29
Methadone (in both formulations) was
priced lower than several morphine formula-
tions in almost all the countries where available
and the most consumed in China, Iran, New
Zealand, Tanzania, and the U.K.30 It is impor-
tant to note that methadone is mostly used in
substitution therapy for dependence syndrome,
but its use as an analgesic has been increasing in
palliative care.31e33
Affordability
New Zealand had the best affordability (nine
medications/formulations available for free).
Monthly treatment costs of morphine oral solid
IRmeasured in the number of days’ wages of the
lowest-paid worker varies greatly (Philippines
29, India 21, and Guatemala 8 days). Many peo-
ple in these countries earn less than the mini-
mum wages used for this study (USD: 2.18,
4.85, and 8.16 per day respectively)23 and live
below the international poverty line of USD
1.25/day,34 indicating that the number of work-
ing days needed to pay the cost of treatmentmay
be higher than the results in this study and that
pain treatment is accessible to only a few who
can afford it.
Governments and policy makers need to take
the necessary steps to ensure that the patients
are able to receive the treatment that they
need. Prices can be reduced by strategies suchas manufacturing the oral morphine in the
country, eliminating taxes and tariffs, regu-
lating markup charges, and regularly moni-
toring the distribution chain. However, these
measures are related to wider aspects in the
respective country such as the Human Develop-
ment Index.35
Limitations
Although the OPW follows a methodology
similar to the one used by HAI/WHO, the
latter does not include controlled medica-
tions. Opioids are internationally controlled;
thus, the availability and pricing are impacted
by additional factors, such as markups re-
sulting from safety and security measures
required by the national laws on the
manufacturing, importation, distribution,
storage, and dispensation. This survey is un-
able to determine the extent of the impact
of these measures on the dispensed price of
the medication.
This study is based on the data collected from
external collaborators, and it is not possible
to determine how rigidly they followed the
instructions.
This study is a one day cross-sectional survey.
Out-of-stock situations occur frequently, espe-
cially in LIC and MLIC, so the results on avail-
ability might differ in a longitudinal survey.
However, the results reflect the situation that
patients in need of opioids may face in any
given day.
The study is based on a sample of data of a
local pharmacy in the selected countries,
which is not representative of the whole coun-
try. However, the fact that pharmacies were
located to major treating centers may indicate
that other pharmacies distant from hospitals
may have fewer medications in stock.
The OPW indicates differences in opioid pri-
ces among different locations. With the excep-
tion of morphine oral solid IR, it does not
take into account the differences in purchasing
power among countries. Future studies using
purchasing power parity should be carried out
tomeasure howpricesmay affect access to other
opioids.Conclusion
The study indicates that patients in LIC and
MIC have less access to opioid medications
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improving their availability and affordability.
Efforts should be made by governments,
health care administrators, and pharmacists
to ensure that opioids are available in local
pharmacies near to the health care facilities
that provide care for life-threatening condi-
tions. Results also show an unexpected favor-
able price difference for fentanyl TPs over IR
morphine, indicating heavy subsidies for fen-
tanyl. Additional studies are needed to iden-
tify the reasons why morphine, which is
cheaper than other medications, is not
included in subsidy programs, even in coun-
tries with limited resources. Although avail-
ability of several opioids and formulations is
desirable, it is also critical to ensure access to
morphine, which has been proven to be effica-
cious and safe for severe pain treatment and
has been classified as an essential medicine
for the treatment of pain by the WHO. Addi-
tional studies are also needed to identify the
extent that factors such as restrictive laws
and regulations have on the dispensed price
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___If NONE of the opioids listed in this study are available at ANY TIME in your country, check this box
___If opioids are available in your country ONLY in hospital pharmacies (and NOT in street pharmacies) check this box
If your country has a tiered system in which medicines (including opioids) are priced according to the person’s income level, report the price that a 
patient earning the lowest minimum wage would have to pay. 
The form will require providing information on the prices for the formulations below. To see samples on how to complete this table, click on 
http://hospicecare.com/opioids/uploads/examples.pdf
Opioid
Check this box if 
the medication is 
NOT available in 
the pharmacy on 
the day of the 
survey
Check this box if 
the medications 
is dispensed 
Free
(at no cost for 
the patient)
If patient has to pay, 
write in numbers the 
amount required to 
pay (in your local 
currency)
Smallest selling 
dose (total units for 
dry formulations or 
total volume for 
liquid formulations)
Fentanyl (transdermal patches)
Hydromorphone ampoule, injectable
Hydromorphone oral solid (tablet or capsule), immediate release
Hydromorphone oral solid (tablet o capsule), prolonged release
Hydromorphone oral liquid (oral solution)
Methadone oral solid (tablet or capsule)
Methadone oral liquid (oral solution)
Morphine ampoule, injectable
Morphine oral solid (tablet or capsule), immediate release 
Morphine oral solid (tablet or capsule), sustained release
Morphine oral liquid (oral solution)
Oxycodone oral solid (tablet or capsule), immediate release
Oxycodone oral solid (tablet or capsule), sustained release
Number of pharmacies you visited before finding one which has AT LEAST ONE opioid in stock (if available in your country)____
Pharmacy address: 
__________________________________________________________________________________________________________
Select the appropriate category (select one): Licensed retail pharmacy ____  Licensed hospital pharmacy:___
Appendix
Sample Data Collection Form
6
5
9
.e1
V
ol.
4
8
N
o.
4
O
ctober
2
0
1
4
D
e
L
im
a
et
al.
